[{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"OpenBench","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Tavros Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Tavros Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Tavros Therapeutics \/ Tavros Therapeutics"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Tavros Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : The collaboration aims to deliver novel precision therapeutics capable of addressing cancer-causing proteins that have eluded traditional small molecule drugs.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $17.5 million

                          May 14, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Vividion Therapeutics

                          Deal Size : $448.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : The multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s AI-enabled screening platform to discover small molecule modulators of up to five oncology targets across an initial 18-month term.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 27, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : OpenBench

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for e...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $17.5 million

                          October 12, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Vividion Therapeutics

                          Deal Size : $448.0 million

                          Deal Type : Collaboration

                          blank